Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.


Experts Discuss Evolving State-of-the-Art Management of Patients With HER2-Positive MBC

Listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss 2 real-world cases of patients with HER2-positive MBC and clinical considerations in the evolving state-of-the-art care treatment landscape.
Thomas Bachelot, MD, PhD
Adam M. Brufsky, MD, PhD
person default
Cristina Saura, MD, PhD
Released: September 21, 2020

In this podcast episode, listen to breast cancer experts Thomas Bachelot, MD, PhD; Adam M. Brufsky, MD, PhD; and Cristina Saura, MD, PhD, discuss clinical considerations for patients with HER2-positive MBC, with topics including:

  • Local therapy in the context of MBC
  • Choice of therapy after progression on available standards of care
  • Choice of trastuzumab deruxtecan and tucatinib based on patient presentation
  • Managing patients with CNS metastases
  • Managing interstitial lung disease

Content based on an online CME program supported by an educational grant from Daiichi Sankyo, Inc.

Link to full program, including associated downloadable slidesets: https://www.clinicaloptions.com/oncology/programs/esmo-breast-sat


Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Daiichi Sankyo, Inc.

Related Content

In this commentary from Clinical Care Options (CCO), experts look ahead to key studies being reported at SABCS 2021 and highlight what data they are most excited to see

Joyce O'Shaughnessy, MD Sara Tolaney, MD, MPH Released: December 6, 2021

Laura M. Spring, MD, discusses the use of abemaciclib in patients with HR-positive, HER2-negative, node-positive early breast cancer, from Clinical Care Options (CCO)

Laura M. Spring, MD Released: November 29, 2021

Commentary from Clinical Care Options (CCO): Maria Arcila, MD, discusses recommendations for testing for NRG1 fusions in patients with solid tumors

person default Maria E. Arcila, MD Released: November 16, 2021

Expert podcast on second-generation TRK inhibitors with Dr. George Demetri and Dr. Alexander Drilon, from Clinical Care Options (CCO)

George D. Demetri, MD Alexander Drilon, MD Released: November 9, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.